Glycated hemoglobin / HbA1c concentration

What acts on it

1. The extract groups showed reduced HbA1c from baseline; treatment assignment was a significant predictor of change in the reported regression.

   C. zeylanicum extract in the 2025 diabetes trial → Glycated hemoglobin / HbA1c concentration source_derived_draftungraded
   Experimental context and source evidence

   evidence_span

   {"source_cache": "artifacts/ceylon-research/41412108.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "41424e14da4786345bad52af19c8ccee1a37f445a402edaa855b87ee01d389b9", "start_char": 0, "end_char": 1887, "text_sha256": "41424e14da4786345bad52af19c8ccee1a37f445a402edaa855b87ee01d389b9"}

   experimental_model

   Three-arm randomized placebo-controlled diabetes trial

   exposure

   210 randomized; 186 completed four months; 250 or 500 mg extract groups

   limitations

   The accessible abstract reports within-baseline changes and regression significance, without a full numeric between-group effect estimate. Do not turn these into a precise placebo-adjusted magnitude.

   nutrient_topic

   Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect. · Ceylon cinnamon / Cinnamomum verum bark preparations

   organism

   Human

   plain_language

   The study reported improved HbA1c, but the accessible abstract does not provide the full treatment-versus-placebo effect size.

   primary_references

   [ceylon-p41412108] Efficacy and Safety of Cinnamomum zeylanicum (Ceylon cinnamon) for diabetes mellitus: a randomized, double blind, placebo-controlled clinical trial. (2025). https://pubmed.ncbi.nlm.nih.gov/41412108/ DOI: 10.1016/j.dsx.2025.103357

   tissue_or_cell_type

   Type 2 diabetes cohort

   Ceylon cinnamon: metabolism, signaling and nutrient connections (2026-09-17) · lines 1182–1193

   AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Three-arm randomized placebo-controlled diabetes trial · source_derived_draft · unverified_draft

   ### ceylon-diabetes-hba1c The extract groups showed reduced HbA1c from baseline; treatment assignment was a significant predictor of change in the reported regression. Condition category: normal nutrient_topic: Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect. plain_language: The study reported improved HbA1c, but the accessible abstract does not provide the full treatment-versus-placebo effect size. organism: Human tissue_or_cell_type: Type 2 diabetes cohort experimental_model: Three-arm randomized placebo-controlled diabetes trial limitations: The accessible abstract reports within-baseline changes and regression significance, without a full numeric between-group effect estimate. Do not turn these into a precise placebo-adjusted magnitude. exposure: 210 randomized; 186 completed four months; 250 or 500 mg extract groups evidence_span: {"source_cache": "artifacts/ceylon-research/41412108.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "41424e14da4786345bad52af19c8ccee1a37f445a402edaa855b87ee01d389b9", "start_char": 0, "end_char": 1887, "text_sha256": "41424e14da4786345bad52af19c8ccee1a37f445a402edaa855b87ee01d389b9"} [ceylon-p41412108] Efficacy and Safety of Cinnamomum zeylanicum (Ceylon cinnamon) for diabetes mellitus: a randomized, double blind, placebo-controlled clinical trial. (2025). https://pubmed.ncbi.nlm.nih.gov/41412108/ DOI: 10.1016/j.dsx.2025.103357

   Complete structured claim and evidence

2. HbA1c decreased in the reported obese dysregulated-diabetes subgroup.

   Broccoli sprout preparation, composition specified per study → Glycated hemoglobin / HbA1c concentration source_derived_draftungraded
   Experimental context and source evidence

   evidence_span

   {"source_cache": "artifacts/sulforaphane-research/28615356.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "65f64f5fa5e84a03d3ba4b647ce94a815fd3bd345486b726e7a54f1a813cab0e", "start_char": 0, "end_char": 1106, "text_sha256": "65f64f5fa5e84a03d3ba4b647ce94a815fd3bd345486b726e7a54f1a813cab0e"}

   experimental_model

   Network-guided preclinical work with a human intervention

   exposure

   Concentrated broccoli sprout extract; obese dysregulated-diabetes subgroup

   limitations

   Model-based mechanism and clinical subgroup outcomes are distinct; no equivalence to metformin in patients is claimed.

   nutrient_topic

   Sulforaphane research collection; topical membership is not evidence of a direct dietary effect. · Sulforaphane / SFN, stereochemistry specified per study

   organism

   Hepatic cell/animal models and humans with type 2 diabetes

   plain_language

   A longer-term glucose marker also changed in that subgroup.

   primary_references

   [sulforaphane-p28615356] Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes. (2017). https://pubmed.ncbi.nlm.nih.gov/28615356/ DOI: 10.1126/scitranslmed.aah4477

   tissue_or_cell_type

   Glucose production and clinical glucose control

   Sulforaphane: formation, electrophile sensing and nutrient connections (2026-09-17) · lines 1165–1176

   AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Network-guided preclinical work with a human intervention · source_derived_draft · unverified_draft

   ### sulforaphane-diabetes-hba1c HbA1c decreased in the reported obese dysregulated-diabetes subgroup. Condition category: normal nutrient_topic: Sulforaphane research collection; topical membership is not evidence of a direct dietary effect. plain_language: A longer-term glucose marker also changed in that subgroup. organism: Hepatic cell/animal models and humans with type 2 diabetes tissue_or_cell_type: Glucose production and clinical glucose control experimental_model: Network-guided preclinical work with a human intervention limitations: Model-based mechanism and clinical subgroup outcomes are distinct; no equivalence to metformin in patients is claimed. exposure: Concentrated broccoli sprout extract; obese dysregulated-diabetes subgroup evidence_span: {"source_cache": "artifacts/sulforaphane-research/28615356.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "65f64f5fa5e84a03d3ba4b647ce94a815fd3bd345486b726e7a54f1a813cab0e", "start_char": 0, "end_char": 1106, "text_sha256": "65f64f5fa5e84a03d3ba4b647ce94a815fd3bd345486b726e7a54f1a813cab0e"} [sulforaphane-p28615356] Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes. (2017). https://pubmed.ncbi.nlm.nih.gov/28615356/ DOI: 10.1126/scitranslmed.aah4477

   Complete structured claim and evidence

3. The combination trial reported a between-group difference in HbA1c change (p=0.03); HbA1c fell 0.54 percentage points within the active-treatment group.

   Chromium(III) picolinate / CrPic → Glycated hemoglobin / HbA1c concentration source_derived_draftungraded
   Experimental context and source evidence

   evidence_span

   {"source_cache": "artifacts/chromium-research/17506119.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "6e79defd1a4209f869bce07c110f0007d02eda63387c2eadc5e014a04c3fc126", "start_char": 0, "end_char": 1739, "text_sha256": "6e79defd1a4209f869bce07c110f0007d02eda63387c2eadc5e014a04c3fc126"}

   experimental_model

   Randomized double-blind placebo-controlled combination trial; 447 enrolled

   exposure

   600 µg Cr(III) as picolinate plus 2 mg biotin/day for 90 days with stable oral diabetes medication

   limitations

   There were no chromium-only or biotin-only arms. The design cannot identify the active ingredient or prove synergy. Baseline-HbA1c subgroup effects are separately limited.

   nutrient_topic

   Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

   organism

   Human with poorly controlled type 2 diabetes

   plain_language

   The two-ingredient treatment improved the average long-term glucose marker, but the contribution of each ingredient is unresolved.

   primary_references

   [chromium-p17506119] Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. (2008). https://pubmed.ncbi.nlm.nih.gov/17506119/ DOI: 10.1002/dmrr.755

   tissue_or_cell_type

   HbA1c and fasting glucose

   Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 692–703

   AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind placebo-controlled combination trial; 447 enrolled · source_derived_draft · unverified_draft

   ### chromium-biotin-combination-hba1c The combination trial reported a between-group difference in HbA1c change (p=0.03); HbA1c fell 0.54 percentage points within the active-treatment group. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The two-ingredient treatment improved the average long-term glucose marker, but the contribution of each ingredient is unresolved. organism: Human with poorly controlled type 2 diabetes tissue_or_cell_type: HbA1c and fasting glucose experimental_model: Randomized double-blind placebo-controlled combination trial; 447 enrolled limitations: There were no chromium-only or biotin-only arms. The design cannot identify the active ingredient or prove synergy. Baseline-HbA1c subgroup effects are separately limited. exposure: 600 µg Cr(III) as picolinate plus 2 mg biotin/day for 90 days with stable oral diabetes medication evidence_span: {"source_cache": "artifacts/chromium-research/17506119.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "6e79defd1a4209f869bce07c110f0007d02eda63387c2eadc5e014a04c3fc126", "start_char": 0, "end_char": 1739, "text_sha256": "6e79defd1a4209f869bce07c110f0007d02eda63387c2eadc5e014a04c3fc126"} [chromium-p17506119] Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. (2008). https://pubmed.ncbi.nlm.nih.gov/17506119/ DOI: 10.1002/dmrr.755

   Complete structured claim and evidence

4. HbA1c fell by about 0.4 percentage points in all three groups, with no chromium benefit over placebo.

   Chromium(III) picolinate / CrPic → Glycated hemoglobin / HbA1c concentration source_derived_draftungraded
   Experimental context and source evidence

   evidence_span

   {"source_cache": "artifacts/chromium-research/16505499.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "bd1f6a73f70c17bce17b217555cef0c349bd27e8d2bbbe0573b826217039df59", "start_char": 0, "end_char": 1206, "text_sha256": "bd1f6a73f70c17bce17b217555cef0c349bd27e8d2bbbe0573b826217039df59"}

   experimental_model

   Six-month double-blind randomized placebo-controlled trial

   exposure

   500 or 1,000 µg Cr/day as picolinate; baseline HbA1c >8% and insulin >50 units/day; per-protocol analysis n=46

   limitations

   Per-protocol analysis and selected insulin-treated population. This is a clinically relevant null result, not proof that no person can respond.

   nutrient_topic

   Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

   organism

   Human obese adults with insulin-treated type 2 diabetes

   plain_language

   A later trial did not reproduce the earlier glucose-control benefit.

   primary_references

   [chromium-p16505499] Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. (2006). https://pubmed.ncbi.nlm.nih.gov/16505499/ DOI: 10.2337/diacare.29.03.06.dc05-1453

   tissue_or_cell_type

   HbA1c and secondary metabolic endpoints

   Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 1056–1067

   AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Six-month double-blind randomized placebo-controlled trial · source_derived_draft · unverified_draft

   ### chromium-diabetes-hba1c-null HbA1c fell by about 0.4 percentage points in all three groups, with no chromium benefit over placebo. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: A later trial did not reproduce the earlier glucose-control benefit. organism: Human obese adults with insulin-treated type 2 diabetes tissue_or_cell_type: HbA1c and secondary metabolic endpoints experimental_model: Six-month double-blind randomized placebo-controlled trial limitations: Per-protocol analysis and selected insulin-treated population. This is a clinically relevant null result, not proof that no person can respond. exposure: 500 or 1,000 µg Cr/day as picolinate; baseline HbA1c >8% and insulin >50 units/day; per-protocol analysis n=46 evidence_span: {"source_cache": "artifacts/chromium-research/16505499.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "bd1f6a73f70c17bce17b217555cef0c349bd27e8d2bbbe0573b826217039df59", "start_char": 0, "end_char": 1206, "text_sha256": "bd1f6a73f70c17bce17b217555cef0c349bd27e8d2bbbe0573b826217039df59"} [chromium-p16505499] Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. (2006). https://pubmed.ncbi.nlm.nih.gov/16505499/ DOI: 10.2337/diacare.29.03.06.dc05-1453

   Complete structured claim and evidence

5. After four months, reported HbA1c values were 8.5%, 7.5% and 6.6% in the placebo, 200 µg/day and 1,000 µg/day groups, respectively.

   Chromium(III) picolinate / CrPic → Glycated hemoglobin / HbA1c concentration source_derived_draftungraded
   Experimental context and source evidence

   evidence_span

   {"source_cache": "artifacts/chromium-research/9356027.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69", "start_char": 0, "end_char": 1941, "text_sha256": "9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69"}

   experimental_model

   Randomized three-arm supplementation trial; 180 adults

   exposure

   Placebo, 200 or 1,000 µg Cr/day as picolinate for four months while usual medications continued

   limitations

   Historical single-population trial; response does not diagnose chromium deficiency. Baseline diet, medication context and replication matter; later trials reported null effects.

   nutrient_topic

   Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

   organism

   Human with treated type 2 diabetes

   plain_language

   This trial reported better long-term glucose control with chromium picolinate.

   primary_references

   [chromium-p9356027] Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. (1997). https://pubmed.ncbi.nlm.nih.gov/9356027/ DOI: 10.2337/diab.46.11.1786

   tissue_or_cell_type

   HbA1c, glucose, insulin and lipids

   Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 1017–1028

   AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized three-arm supplementation trial; 180 adults · source_derived_draft · unverified_draft

   ### chromium-diabetes-hba1c-positive After four months, reported HbA1c values were 8.5%, 7.5% and 6.6% in the placebo, 200 µg/day and 1,000 µg/day groups, respectively. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: This trial reported better long-term glucose control with chromium picolinate. organism: Human with treated type 2 diabetes tissue_or_cell_type: HbA1c, glucose, insulin and lipids experimental_model: Randomized three-arm supplementation trial; 180 adults limitations: Historical single-population trial; response does not diagnose chromium deficiency. Baseline diet, medication context and replication matter; later trials reported null effects. exposure: Placebo, 200 or 1,000 µg Cr/day as picolinate for four months while usual medications continued evidence_span: {"source_cache": "artifacts/chromium-research/9356027.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69", "start_char": 0, "end_char": 1941, "text_sha256": "9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69"} [chromium-p9356027] Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. (1997). https://pubmed.ncbi.nlm.nih.gov/9356027/ DOI: 10.2337/diab.46.11.1786

   Complete structured claim and evidence

6. HbA1c, fasting glucose and the lipid profile did not change significantly across the study’s groups.

   Chromium(III) picolinate / CrPic → Glycated hemoglobin / HbA1c concentration source_derived_draftungraded
   Experimental context and source evidence

   evidence_span

   {"source_cache": "artifacts/chromium-research/31593637.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9", "start_char": 0, "end_char": 1523, "text_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9"}

   experimental_model

   Four-arm randomized supplementation trial; 92 participants

   exposure

   Four months; vitamin D3 50,000 IU/week, chromium picolinate reported as 500 µg/day, both or placebo

   limitations

   Study regimens are historical exposures, not recommendations. Stable versus rising HOMA-IR does not show direct mediation by TNF-alpha; no molecular target was tested.

   nutrient_topic

   Chromium research collection; topical membership is not evidence of a direct dietary effect. · Chromium

   organism

   Human with type 2 diabetes

   plain_language

   The reported HOMA-IR pattern did not translate into a demonstrated HbA1c improvement.

   primary_references

   [chromium-p31593637] The effects of chromium and vitamin D3 co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial. (2020). https://pubmed.ncbi.nlm.nih.gov/31593637/ DOI: 10.1139/apnm-2019-0113

   tissue_or_cell_type

   Blood glycemia, HOMA-IR and TNF-alpha

   Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17) · lines 679–690

   AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Four-arm randomized supplementation trial; 92 participants · source_derived_draft · unverified_draft

   ### chromium-vitd-hba1c-null HbA1c, fasting glucose and the lipid profile did not change significantly across the study’s groups. Condition category: normal nutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect. plain_language: The reported HOMA-IR pattern did not translate into a demonstrated HbA1c improvement. organism: Human with type 2 diabetes tissue_or_cell_type: Blood glycemia, HOMA-IR and TNF-alpha experimental_model: Four-arm randomized supplementation trial; 92 participants limitations: Study regimens are historical exposures, not recommendations. Stable versus rising HOMA-IR does not show direct mediation by TNF-alpha; no molecular target was tested. exposure: Four months; vitamin D3 50,000 IU/week, chromium picolinate reported as 500 µg/day, both or placebo evidence_span: {"source_cache": "artifacts/chromium-research/31593637.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9", "start_char": 0, "end_char": 1523, "text_sha256": "9815b482cfc5655a11a3192ca21b47c903e8722a3b9b9e7d770e92e9fb94bfa9"} [chromium-p31593637] The effects of chromium and vitamin D3 co-supplementation on insulin resistance and tumor necrosis factor-alpha in type 2 diabetes: a randomized placebo-controlled trial. (2020). https://pubmed.ncbi.nlm.nih.gov/31593637/ DOI: 10.1139/apnm-2019-0113

   Complete structured claim and evidence

7. Berberine lowered HbA1c from 7.5% to 6.6% in its treatment arm, with a significant difference from placebo.

   Berberine → Glycated hemoglobin / HbA1c concentration source_derived_draftungraded
   Experimental context and source evidence

   evidence_span

   {"source_cache": "artifacts/berberine-research/18397984.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0711d6853427d4b78af4704fd7630e08ed0f83d599311156dbc8570efd88dce2", "start_char": 0, "end_char": 1715, "text_sha256": "0711d6853427d4b78af4704fd7630e08ed0f83d599311156dbc8570efd88dce2"}

   experimental_model

   Randomized placebo-controlled clinical trial

   exposure

   Berberine 1 g/day for three months

   limitations

   Short trial with surrogate endpoints. Within-arm clamp improvement was not statistically significant versus placebo; lower glucose does not identify one causal enzyme.

   nutrient_topic

   Berberine research collection; topical membership is not evidence of a direct dietary effect. · Berberine

   organism

   116 people with type 2 diabetes and dyslipidemia

   plain_language

   This trial measured improved glycemic control in people with diabetes.

   primary_references

   [berberine-p18397984] Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. (2008). https://pubmed.ncbi.nlm.nih.gov/18397984/ DOI: 10.1210/jc.2007-2404

   tissue_or_cell_type

   Glycemic markers, lipids and insulin sensitivity

   Berberine: metabolism, nutrient connections and drug interactions (2026-09-17) · lines 1182–1193

   AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized placebo-controlled clinical trial · source_derived_draft · unverified_draft

   ### berberine-diabetes-hba1c Berberine lowered HbA1c from 7.5% to 6.6% in its treatment arm, with a significant difference from placebo. Condition category: normal nutrient_topic: Berberine research collection; topical membership is not evidence of a direct dietary effect. plain_language: This trial measured improved glycemic control in people with diabetes. organism: 116 people with type 2 diabetes and dyslipidemia tissue_or_cell_type: Glycemic markers, lipids and insulin sensitivity experimental_model: Randomized placebo-controlled clinical trial limitations: Short trial with surrogate endpoints. Within-arm clamp improvement was not statistically significant versus placebo; lower glucose does not identify one causal enzyme. exposure: Berberine 1 g/day for three months evidence_span: {"source_cache": "artifacts/berberine-research/18397984.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0711d6853427d4b78af4704fd7630e08ed0f83d599311156dbc8570efd88dce2", "start_char": 0, "end_char": 1715, "text_sha256": "0711d6853427d4b78af4704fd7630e08ed0f83d599311156dbc8570efd88dce2"} [berberine-p18397984] Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. (2008). https://pubmed.ncbi.nlm.nih.gov/18397984/ DOI: 10.1210/jc.2007-2404

   Complete structured claim and evidence

8. A 36-person pilot reported similar glucose-lowering responses in berberine and metformin groups.

   Berberine → Glycated hemoglobin / HbA1c concentration source_derived_draftungraded
   Experimental context and source evidence

   evidence_span

   {"source_cache": "artifacts/berberine-research/18442638.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0d85d3f03994b65869cd6c52fb46d679f220e4221a6764b38833468818551b66", "start_char": 0, "end_char": 1655, "text_sha256": "0d85d3f03994b65869cd6c52fb46d679f220e4221a6764b38833468818551b66"}

   experimental_model

   Small randomized comparison plus uncontrolled add-on cohort

   exposure

   Three-month berberine/metformin comparison and berberine add-on study

   limitations

   Small pilot, not an equivalence trial proving berberine substitutes for metformin. Add-on cohort lacks a concurrent placebo comparison.

   nutrient_topic

   Berberine research collection; topical membership is not evidence of a direct dietary effect. · Berberine

   organism

   Adults with type 2 diabetes

   plain_language

   A small comparison is encouraging but does not establish interchangeable clinical treatment.

   primary_references

   [berberine-p18442638] Efficacy of berberine in patients with type 2 diabetes mellitus. (2008). https://pubmed.ncbi.nlm.nih.gov/18442638/ DOI: 10.1016/j.metabol.2008.01.013

   tissue_or_cell_type

   Glycemic control and gastrointestinal effects

   Berberine: metabolism, nutrient connections and drug interactions (2026-09-17) · lines 1221–1232

   AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Small randomized comparison plus uncontrolled add-on cohort · source_derived_draft · unverified_draft

   ### berberine-pilot-metformin A 36-person pilot reported similar glucose-lowering responses in berberine and metformin groups. Condition category: normal nutrient_topic: Berberine research collection; topical membership is not evidence of a direct dietary effect. plain_language: A small comparison is encouraging but does not establish interchangeable clinical treatment. organism: Adults with type 2 diabetes tissue_or_cell_type: Glycemic control and gastrointestinal effects experimental_model: Small randomized comparison plus uncontrolled add-on cohort limitations: Small pilot, not an equivalence trial proving berberine substitutes for metformin. Add-on cohort lacks a concurrent placebo comparison. exposure: Three-month berberine/metformin comparison and berberine add-on study evidence_span: {"source_cache": "artifacts/berberine-research/18442638.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "0d85d3f03994b65869cd6c52fb46d679f220e4221a6764b38833468818551b66", "start_char": 0, "end_char": 1655, "text_sha256": "0d85d3f03994b65869cd6c52fb46d679f220e4221a6764b38833468818551b66"} [berberine-p18442638] Efficacy of berberine in patients with type 2 diabetes mellitus. (2008). https://pubmed.ncbi.nlm.nih.gov/18442638/ DOI: 10.1016/j.metabol.2008.01.013

   Complete structured claim and evidence

9. HbA1c changed by -0.99 percentage points with berberine alone versus -0.59 with placebo over 12 weeks.

   Berberine → Glycated hemoglobin / HbA1c concentration source_derived_draftungraded
   Experimental context and source evidence

   evidence_span

   {"source_cache": "artifacts/berberine-research/33024120.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "5dbbfd240d55ac62d2f48263f25e5543e47aa4a91d7711637fbacc543ce54bd9", "start_char": 0, "end_char": 1283, "text_sha256": "5dbbfd240d55ac62d2f48263f25e5543e47aa4a91d7711637fbacc543ce54bd9"}

   experimental_model

   Multicenter randomized double-blind four-arm trial with metagenomics and microbial validation

   exposure

   Twelve weeks of berberine, probiotics, both or placebo after one week of gentamycin pretreatment

   limitations

   Antibiotic run-in and Chinese drug-naive population limit generalization. Microbial mediation is supported but not proof it explains every effect. Probiotic addition did not show a clear extra HbA1c reduction in the reported estimates.

   nutrient_topic

   Berberine research collection; topical membership is not evidence of a direct dietary effect. · Berberine

   organism

   409 newly diagnosed type 2 diabetes patients; separate bacterial experiments

   plain_language

   The treatment difference was about 0.40 percentage points; the full within-group drop is not the placebo-adjusted effect.

   primary_references

   [berberine-p33024120] Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). (2020). https://pubmed.ncbi.nlm.nih.gov/33024120/ DOI: 10.1038/s41467-020-18414-8

   tissue_or_cell_type

   Glycemia, gut microbiome and bile-acid transformation

   Berberine: metabolism, nutrient connections and drug interactions (2026-09-17) · lines 1130–1141

   AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Multicenter randomized double-blind four-arm trial with metagenomics and microbial validation · source_derived_draft · unverified_draft

   ### berberine-premote-hba1c HbA1c changed by -0.99 percentage points with berberine alone versus -0.59 with placebo over 12 weeks. Condition category: normal nutrient_topic: Berberine research collection; topical membership is not evidence of a direct dietary effect. plain_language: The treatment difference was about 0.40 percentage points; the full within-group drop is not the placebo-adjusted effect. organism: 409 newly diagnosed type 2 diabetes patients; separate bacterial experiments tissue_or_cell_type: Glycemia, gut microbiome and bile-acid transformation experimental_model: Multicenter randomized double-blind four-arm trial with metagenomics and microbial validation limitations: Antibiotic run-in and Chinese drug-naive population limit generalization. Microbial mediation is supported but not proof it explains every effect. Probiotic addition did not show a clear extra HbA1c reduction in the reported estimates. exposure: Twelve weeks of berberine, probiotics, both or placebo after one week of gentamycin pretreatment evidence_span: {"source_cache": "artifacts/berberine-research/33024120.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "5dbbfd240d55ac62d2f48263f25e5543e47aa4a91d7711637fbacc543ce54bd9", "start_char": 0, "end_char": 1283, "text_sha256": "5dbbfd240d55ac62d2f48263f25e5543e47aa4a91d7711637fbacc543ce54bd9"} [berberine-p33024120] Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). (2020). https://pubmed.ncbi.nlm.nih.gov/33024120/ DOI: 10.1038/s41467-020-18414-8

   Complete structured claim and evidence

10. The berberine-plus-probiotics arm had an HbA1c change of -1.04 percentage points compared with -0.99 for berberine alone.

    Berberine → Glycated hemoglobin / HbA1c concentration source_derived_draftungraded
    Experimental context and source evidence

    evidence_span

    {"source_cache": "artifacts/berberine-research/33024120.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "5dbbfd240d55ac62d2f48263f25e5543e47aa4a91d7711637fbacc543ce54bd9", "start_char": 0, "end_char": 1283, "text_sha256": "5dbbfd240d55ac62d2f48263f25e5543e47aa4a91d7711637fbacc543ce54bd9"}

    experimental_model

    Multicenter randomized double-blind four-arm trial with metagenomics and microbial validation

    exposure

    Twelve weeks of berberine, probiotics, both or placebo after one week of gentamycin pretreatment

    limitations

    Antibiotic run-in and Chinese drug-naive population limit generalization. Microbial mediation is supported but not proof it explains every effect. Probiotic addition did not show a clear extra HbA1c reduction in the reported estimates.

    nutrient_topic

    Berberine research collection; topical membership is not evidence of a direct dietary effect. · Berberine

    organism

    409 newly diagnosed type 2 diabetes patients; separate bacterial experiments

    plain_language

    These results do not demonstrate a large added benefit from this probiotic mixture.

    primary_references

    [berberine-p33024120] Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). (2020). https://pubmed.ncbi.nlm.nih.gov/33024120/ DOI: 10.1038/s41467-020-18414-8

    tissue_or_cell_type

    Glycemia, gut microbiome and bile-acid transformation

    Berberine: metabolism, nutrient connections and drug interactions (2026-09-17) · lines 1143–1154

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Multicenter randomized double-blind four-arm trial with metagenomics and microbial validation · source_derived_draft · unverified_draft

    ### berberine-premote-probiotics The berberine-plus-probiotics arm had an HbA1c change of -1.04 percentage points compared with -0.99 for berberine alone. Condition category: normal nutrient_topic: Berberine research collection; topical membership is not evidence of a direct dietary effect. plain_language: These results do not demonstrate a large added benefit from this probiotic mixture. organism: 409 newly diagnosed type 2 diabetes patients; separate bacterial experiments tissue_or_cell_type: Glycemia, gut microbiome and bile-acid transformation experimental_model: Multicenter randomized double-blind four-arm trial with metagenomics and microbial validation limitations: Antibiotic run-in and Chinese drug-naive population limit generalization. Microbial mediation is supported but not proof it explains every effect. Probiotic addition did not show a clear extra HbA1c reduction in the reported estimates. exposure: Twelve weeks of berberine, probiotics, both or placebo after one week of gentamycin pretreatment evidence_span: {"source_cache": "artifacts/berberine-research/33024120.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "5dbbfd240d55ac62d2f48263f25e5543e47aa4a91d7711637fbacc543ce54bd9", "start_char": 0, "end_char": 1283, "text_sha256": "5dbbfd240d55ac62d2f48263f25e5543e47aa4a91d7711637fbacc543ce54bd9"} [berberine-p33024120] Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). (2020). https://pubmed.ncbi.nlm.nih.gov/33024120/ DOI: 10.1038/s41467-020-18414-8

    Complete structured claim and evidence

11. The SLC47A1 rs2289669 A allele was associated with a 0.30% larger HbA1c reduction per allele during metformin treatment.

    Human multidrug and toxin extrusion protein 1 / MATE1 / SLC47A1 → Glycated hemoglobin / HbA1c concentration source_derived_draftungraded
    Experimental context and source evidence

    evidence_span

    {"source_cache": "artifacts/metformin-research/19228809.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e90099f316586ff994eff67af58f075f654413a68d8605e869755e9b8c68adb3", "start_char": 0, "end_char": 1383, "text_sha256": "e90099f316586ff994eff67af58f075f654413a68d8605e869755e9b8c68adb3"}

    experimental_model

    Pharmacogenetic analysis of 116 incident metformin users in the Rotterdam Study

    exposure

    Twelve tagging SNPs in SLC47A1 against change in HbA1c

    limitations

    A preliminary association in a small sample that the authors say requires replication; no mechanism was measured.

    nutrient_topic

    Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake. · Metformin

    organism

    Human

    plain_language

    How quickly the body clears the drug tracks with how much it lowers long-term glucose.

    primary_references

    [metformin-p19228809] Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. (2009). https://pubmed.ncbi.nlm.nih.gov/19228809/ DOI: 10.2337/db08-1028

    tissue_or_cell_type

    Glycaemic response

    Metformin: transport, molecular targets, gut mechanisms and nutrient interactions (2026-09-19) · lines 372–383

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Pharmacogenetic analysis of 116 incident metformin users in the Rotterdam Study · source_derived_draft · unverified_draft

    ### metformin-mate1-variant-response The SLC47A1 rs2289669 A allele was associated with a 0.30% larger HbA1c reduction per allele during metformin treatment. Condition category: normal nutrient_topic: Metformin research collection; topical membership is not evidence of a direct clinical effect, and pharmacological exposure is not dietary intake. plain_language: How quickly the body clears the drug tracks with how much it lowers long-term glucose. organism: Human tissue_or_cell_type: Glycaemic response experimental_model: Pharmacogenetic analysis of 116 incident metformin users in the Rotterdam Study limitations: A preliminary association in a small sample that the authors say requires replication; no mechanism was measured. exposure: Twelve tagging SNPs in SLC47A1 against change in HbA1c evidence_span: {"source_cache": "artifacts/metformin-research/19228809.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e90099f316586ff994eff67af58f075f654413a68d8605e869755e9b8c68adb3", "start_char": 0, "end_char": 1383, "text_sha256": "e90099f316586ff994eff67af58f075f654413a68d8605e869755e9b8c68adb3"} [metformin-p19228809] Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. (2009). https://pubmed.ncbi.nlm.nih.gov/19228809/ DOI: 10.2337/db08-1028

    Complete structured claim and evidence